Literature DB >> 12540418

Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D.

Paul Glendenning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12540418     DOI： 10.1093/ajcn/77.2.522

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN： 0002-9165            Impact factor:   7.045


× No keyword cloud information.
  4 in total

1.  Standardised, metabolite-specific assays with validated decision limits: utopian ideal or achievable goal?

Authors:  Paul Glendenning
Journal:  Clin Biochem Rev       Date:  2005-02

2.  The problem of low levels of vitamin D and osteoporosis: use of combination therapy with alendronic acid and colecalciferol (vitamin D3).

Authors:  Sol Epstein
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Associations of 25-hydroxyvitamin D2 and D3 with cardiovascular risk factors in childhood: cross-sectional findings from the Avon Longitudinal Study of Parents and Children.

Authors:  Dylan M Williams; Abigail Fraser; Adrian Sayers; William D Fraser; Aroon Hingorani; John Deanfield; George Davey Smith; Naveed Sattar; Debbie A Lawlor
Journal:  J Clin Endocrinol Metab       Date:  2012-02-16       Impact factor: 5.958

Review 4.  Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein - A position paper from the IFCC Committee on bone metabolism.

Authors:  Konstantinos Makris; Harjit P Bhattoa; Etienne Cavalier; Karen Phinney; Christopher T Sempos; Candice Z Ulmer; Samuel D Vasikaran; Hubert Vesper; Annemieke C Heijboer
Journal:  Clin Chim Acta       Date:  2021-03-10       Impact factor: 6.314
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.